Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study

被引：0

作者：

Takeshi Kato

Yoshinori Kagawa

Yasutoshi Kuboki

Makio Gamoh

Yoshito Komatsu

Hirofumi Yasui

Hironaga Satake

Eiji Oki

Hiroaki Tanioka

Masahito Kotaka

Akitaka Makiyama

Tadamichi Denda

Masahiro Goto

Takayuki Yoshino

Kentaro Yamazaki

Junpei Soeda

Kazunori Shibuya

Masaru Iwata

Koji Oba

Kensei Yamaguchi

机构：

[1] National Hospital Organization Osaka National Hospital,Gastroenterological Chemotherapy Department

[2] Kansai Rosai Hospital,Cancer Treatment Center

[3] National Cancer Center Hospital East,undefined

[4] Osaki Citizen Hospital,undefined

[5] Furukawa Honami,undefined

[6] Hokkaido University Hospital,undefined

[7] Shizuoka Cancer Center,undefined

[8] Kobe City Medical Center General Hospital,undefined

[9] Kyushu University,undefined

[10] Okayama Rosai Hospital,undefined

[11] Sano Hospital,undefined

[12] Japan Community Healthcare Organization Kyushu Hospital,undefined

[13] Gifu University Hospital,undefined

[14] Chiba Cancer Center,undefined

[15] Osaka Medical College Hospital,undefined

[16] Takeda Pharmaceutical Company,undefined

[17] University of Tokyo,undefined

[18] Cancer Institute Hospital of Japanese Foundation for Cancer Research,undefined

[19] Kansai Medical University Hospital,undefined

[20] Medical Oncology Kawasaki Medical School,undefined

来源：

International Journal of Clinical Oncology | 2021年 / 26卷

关键词：

Salvage line; Anti-EGFR antibody; Phase 1/2 clinical trial; Oral nucleoside anti-tumour agent; Outcomes;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1238 / 1247

页数：9

共 50 条

[1] Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study
Kato, Takeshi
Kagawa, Yoshinori
Kuboki, Yasutoshi
Gamoh, Makio
Komatsu, Yoshito
Yasui, Hirofumi
Satake, Hironaga
Oki, Eiji
Tanioka, Hiroaki
Kotaka, Masahito
Makiyama, Akitaka
Denda, Tadamichi
Goto, Masahiro
Yoshino, Takayuki
Yamazaki, Kentaro
Soeda, Junpei
Shibuya, Kazunori
Iwata, Masaru
Oba, Koji
Yamaguchi, Kensei
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (07) : 1238 - 1247
[2] Phase IB/II first line panitumumab, irinotecan, trifluridine/tipiracil in RAS wild-type patients with metastatic colorectal cancer: PIT study.
Price, Timothy Jay
Joshi, Rohit
Karapetis, Christos Stelios
Cooper, Pam
Hocking, Chris
Singhal, Nimit
Townsend, Amanda Rose
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] PIT Study Design: Phase IB/II First Line Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS Wild-Type Patients with Metastatic Colorectal Cancer
Price, T.
Rico, G. Tapia
Williams, J.
Yeend, S.
Lo, L.
Patel, D.
Tebbutt, N.
Shapiro, J.
Burge, M.
Gebski, V.
Townsend, A.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 72 - 72
[4] APOLLON study: a phase I/II study for the safety and efficacy of panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapy
Yamaguchi, K.
Komatsu, Y.
Oki, E.
Yoshino, T.
Yamazaki, K.
Shibuya, K.
Oba, K.
Kato, T.
ANNALS OF ONCOLOGY, 2016, 27
[5] Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.
Komatsu, Yoshito
Kato, Takeshi
Kagawa, Yoshinori
Yoshino, Takayuki
Kuboki, Yasutoshi
Gamoh, Makio
Yasui, Hirofumi
Yamazaki, Kentaro
Satake, Hironaga
Goto, Masahiro
Tanioka, Hiroaki
Oki, Eiji
Kotaka, Masahito
Makiyama, Akitaka
Denda, Tadamichi
Soeda, Junpei
Shibuya, Kazunori
Iwata, Masaru
Oba, Koji
Yamaguchi, Kensei
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[6] Safety and efficacy of trifluridine/tipiracil plus bevacizumab in RAS mutated patients with metastatic colorectal cancer
Michalaki, Vasiliki
Theodosopoulos, Thedosios
Vezakis, Antonios
Papaconstantinou, Ioannis
Kontis, Ioannis
Dafnios, Nikolaos
Frangoulidis, George
Karandrea, Despina
Papadimitriou, Christos
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
Troiani, Teresa
Martinelli, Erika
Ciardiello, Davide
Zanaletti, Nicoletta
Cardone, Claudia
Borrelli, Carola
Avallone, Antonio
Falcone, Alfredo
Maiello, Evaristo
Bordonaro, Roberto
Santini, Daniele
Garufi, Carlo
De Braud, Filippo G.
Pinto, Carmine
Gridelli, Cesare
Ciardiello, Fortunato
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[8] TALLISUR Phase IV study of trifluridine/tipiracil (FTD/TPI) in patients with pre-treated metastatic Colorectal Cancer (mCRC) - subgroup analysis
Karthaus, M.
Weiss, L.
Riera-Knorrenschild, J.
Kretschmar, A.
Welslau, M.
Vehling-Kaiser, U.
Pelz, H.
Ettrich, T.
Held, S.
Klein, A.
Hess, J.
Reislaender, T.
Heinemann, V.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 160 - 160
[9] APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).
Kuboki, Yasutoshi
Yoshino, Takayuki
Kato, Takeshi
Kagawa, Yoshinori
Gamoh, Makio
Yasui, Hirofumi
Yamazaki, Kentaro
Komatsu, Yoshito
Satake, Hironaga
Goto, Masahiro
Tanioka, Hiroaki
Oki, Eiji
Kotaka, Masahito
Makiyama, Akitaka
Denda, Tadamichi
Soeda, Junpei
Shibuya, Kazunori
Iwata, Masaru
Oba, Koji
Yamaguchi, Kensei
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] A phase I/II study for panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer (APOLLON study): Phase I results.
Kato, Takeshi
Kagawa, Yoshinori
Komatsu, Yoshito
Oki, Eiji
Yoshino, Takayuki
Yamazaki, Kentaro
Yasui, Hirofumi
Satake, Hironaga
Shibuya, Kazunori
Oba, Koji
Yamaguchi, Kensei
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)

← 1 2 3 4 5 →